论文部分内容阅读
目的:探讨卡培他滨联合奥沙利铂治疗直肠癌的疗效及其对血清MMP-9水平的影响。方法:选取Ⅳ期直肠癌患者44例,随机分为观察组与对照组,每组各22例。对照组予以5-氟尿嘧啶+亚叶酸钙的传统化疗方案,观察组予以卡培他滨+奥沙利铂方案,均治疗12周。于治疗后,观察两组患者的近期疗效、血清MMP-9水平,治疗过程中的不良反应,随访观察无进展生存期(PFS)和总生存期(OS)。结果:治疗后观察组患者PR、RR、DCR均高于对照组,而PD低于对照组;观察组血清MMP-9水平低于对照组;观察组与对照组不良反应发生率13.64%、31.82%;观察组中位PFS、中位OS均长于对照组,差异均具有统计学意义(P值<0.05或P值<0.01)。结论:卡培他滨联合奥沙利铂治疗直肠癌具有较好的近期临床疗效和随访结果,抑制了MMP-9的活性,且具有良好的导向作用,全身毒副作用低,可能是晚期直肠癌治疗比较优化的化疗方案之一。
Objective: To investigate the curative effect of capecitabine combined with oxaliplatin on rectal cancer and its effect on serum MMP-9 level. Methods: Forty-four patients with stage Ⅳ rectal cancer were randomly divided into observation group and control group, with 22 cases in each group. The control group was given 5-fluorouracil + leucovorin chemotherapy program, the observation group was given capecitabine + oxaliplatin regimen, were treated for 12 weeks. After treatment, the short-term effect, serum MMP-9 level and adverse reactions during the treatment were observed. The progression-free survival (PFS) and overall survival (OS) were followed up. Results: After treatment, the PR, RR and DCR in observation group were higher than those in control group, while PD was lower than that in control group. The serum MMP-9 level in observation group was lower than that in control group. The incidence of adverse reactions in observation group and control group was 13.64% and 31.82 %. The median PFS and median OS in the observation group were longer than those in the control group, with statistical significance (P <0.05 or P <0.01). Conclusion: Capecitabine combined with oxaliplatin in the treatment of rectal cancer has good clinical efficacy and follow-up results, inhibits the activity of MMP-9, and has a good guiding role, low systemic side effects, may be advanced rectal cancer Treatment of one of the more optimized chemotherapy.